Praziquantel promotes protection against Schistosoma japonicum infection in mice

Acta Trop. 2023 May:241:106874. doi: 10.1016/j.actatropica.2023.106874. Epub 2023 Mar 1.

Abstract

Praziquantel (PZQ) is the first line drug for the treatment of schistosomiasis. Several studies have confirmed that PZQ regulates host immunity, and we have recently found that pretreatment with PZQ enhances resistance against Schistosoma japonicum infection in buffaloes. We speculate that PZQ induces physiological changes in mice that prevent S. japonicum infection. To test this hypothesis and provide a practical measure to prevent S. japonicum infection, we determined the effective dose (the minimum dose), protection period and onset time of protection by comparing the worm burden, female worm burden and egg burden in PZQ-pretreated mice and blank control mice. Morphological differences between parasites were observed by measuring the total worm length, oral sucker, ventral sucker and ovary. The levels of cytokines, nitrogen monoxide (NO), 5-hydroxytryptamine (5-HT) and specific antibodies were measured using kits or soluble worm antigens. Hematological indicators on day 0 were analyzed in mice that received PZQ on days -15, -18, -19, -20, -21 and -22. The PZQ concentrations in plasma and blood cells were monitored using high performance liquid chromatography (HPLC). The effective dose was found to be two oral administrations (interval of 24 h) at 300 mg/kg body weight (BW) or one injection at 200 mg/kg BW, and the protection period of PZQ injection was 18 days. The optimal preventive effect was observed at two days post-administration, with a >92% worm reduction rate and significant worm reduction until 21 days after administration. Adult worms from PZQ-pretreated mice were runtish showing a shorter length, smaller organs and fewer eggs in the uteri of females. Detection of cytokines, NO, 5-HT and hematological indicators showed that PZQ induced immune-physiological changes, including higher levels of NO, IFN-γ and IL-2, and a lower level of TGF-β. No significant difference in the anti-S. japonicum specific antibody levels was observed. The PZQ concentrations in plasma and blood cells 8 and 15 days post-administration were lower than the detection limit. Our results confirmed that pretreatment with PZQ promotes the protection of mice against S. japonicum infection within 18 days. Although we observed some immune-physiological changes in the PZQ-pretreated mice, the exact mechanisms involved in the preventive effect require further study.

Keywords: Mice; Praziquantel; Prevention; Schistosoma japonicum.

MeSH terms

  • Administration, Oral
  • Animals
  • Anthelmintics* / therapeutic use
  • Antibodies
  • Female
  • Mice
  • Praziquantel / therapeutic use
  • Schistosoma japonicum* / physiology
  • Schistosoma mansoni
  • Schistosomiasis japonica* / drug therapy
  • Schistosomiasis japonica* / parasitology
  • Schistosomiasis japonica* / prevention & control
  • Serotonin / pharmacology
  • Serotonin / therapeutic use

Substances

  • Praziquantel
  • Serotonin
  • Antibodies
  • Anthelmintics